Drug reimbursement policies in Canada - Need for improved access to critical therapies

Annals of Pharmacotherapy

Volumn 42, Issue 6, 2008, Pages 869-873

  LeLorier, Jacques ^a   Bell, Alan ^b   Bougher, David J ^c   Cox, Jafna L ^d   Turpie, Alexander G G ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^c Dalhousie University ^*

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Health outcomes health policy; Medications; Reimbursement

Indexed keywords

CANADA; DECISION MAKING; DRUG COST; DRUG FORMULARY; DRUG PROGRAM; DRUG UTILIZATION; EMERGENCY CARE; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; INTENSIVE CARE; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; TREATMENT OUTCOME;

CANADA; DECISION MAKING; DRUG COSTS; FORMULARIES; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; PHARMACEUTICAL PREPARATIONS; REIMBURSEMENT MECHANISMS; TIME FACTORS;

EID: 44649120761     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K373     Document Type: Note

References (21)

1. Canadian Institute of Health Information. Health care spending to reach $142 billion this year. www.cihi.ca/cihiweb/dispPage.jsp?cw_page= media_07dec2005_e (accessed 2007 Jan 9).
2. Anis AH, Guh D, Wang Xh. A dog's breakfast: prescription drug coverage varies widely across Canada. Med Care 2001;39:312-4.
3. Montague T, Cavanaugh S. Seeking value in pharmaceutical care: balancing quality, access and efficiency. Healthc Pap 2004;4:51-8.
4. Laupacis A. University of British Columbia's Center for Health Services and Policy Research conference: "Towards a National Pharmaceutical Strategy - Lessons from Abroad," February 9-10, 2006.
5. MacDonald K, Potvin K. Interprovincial variation in access to publicly funded pharmaceuticals. Can Pharm J 2004;137:29-34.
6. Polygenis D. Plavix section 8 surveillance study (abstract). Can J Clin Pharmacol 2004;11:e118. Presented at the 2004 Canadian Association of Population Therapeutics meeting, Winnipeg, MB, Canada, June 3-8, 2004. www.cjcp.ca/pdf/Winnipeg_Abstracts_CJCP.pdf (accessed 2008 May 2).
7. British Columbia PharmaCare. Special authority process. www.healthservices.gov.bc.ca/pharme/sa/sa2answer.html (accessed 2007 Oct 24).
8. The Newfoundland and Labrador Prescription Drug Program (NLPDP) Special Authorization Request Form. www.health.gov.nl.ca/health/nlpdp/Inhibitors/ standard_specauth_form.pdf (accessed 2007 Oct 24).
9. Régie de l'assurance maladie du Québec. Liste de médicaments - régime général d'assurance médicaments (médicaments d'exception), December 2006. www.ramq.gouv.qc.ca/fr/professionnels/listmed/pdf/modification/annexe_9.pdf (accessed 2007 Jan 10).
10. Alberta Health and Wellness. Drug benefit list, January 1, 2007. www.ab.bluecross.ca/dbl/pdfs/ahwdbl_sec3.pdf (accessed 2007 Jan 10).
11. Ontario Ministry of Health and Long-Term Care. 2005/6 Report card for the Ontario Drug Benefit Program, February 2007. www.health.gov.on.ca/english/ public/pub/ministry_reports/odb_report05/odb_rep_05_06.pdf (accessed 2008 Feb 20).
12. Report of the Reference Drug Program Consultation Panel to the Honourable Sindi Hawkins Minister of Health Planning British Columbia. April 5,2002. www.health.gov.bc.ca/library/publications/year/2002/rdppanel.pdf (accessed 2007 Oct 24).
13. Herrier RN, Spencer JR, Davis CD. Case study using descriptive analysis to estimate hidden costs in processing third party prescriptions. J Am Pharm Assoc 2000;40:658-65.
14. Dorais M, LeLorier J. Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidinediones (TZDs). Can J Clin Pharmacol 2008;15:e15-21. Epub 9 Jan 2008.
15. Rothwell PM, Giles MF, Chandratheya A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007;370:1432-42. DOI 10.1016/S0140-6736(07)61448-2
16. Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 2002;62(suppl 1):65-78.
17. Ackman ML, Graham MM, Hui C, Tsuyuki RT. Effect of a prior authorization process on antiplatelet therapy and outcomes in patients prescribed clopidogrel following coronary stenting. Can J Cardiol 2006;22:1205-8.
18. Sheehy O, LeLorier J, Rinfret S. Restrictive access to clopidogrel and mortality following coronary stent implantation. Can Med Assoc J 2008;178:413-20.
19. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 2004;351:2187-94. DOI 10.1056/NEJMsa042770
20. Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. Br Med J 2004;328:560. Epub 24 Feb 2004. DOI 10.1136/bmj.38020. 698194.F6
21. ECON Centre for Economic Analysis. Evaluation of the reference pricing system for medicines. (Prepared for the Norwegian Ministry of Health and Social Services, Oslo, Norway), 2000:41.